How China Is Reshaping Global Clinical Development in Oncology
China’s role in global clinical development has changed—rapidly and materially. Once viewed primarily as a regional market, China is now shaping the pace, scale, and feasibility of oncology trials worldwide.
Insights shared at the ESMO 2025 highlight how regulatory acceleration, large patient populations, and measurable improvements in trial quality are reshaping sponsor decision-making. From shortened IND review timelines to faster enrollment and narrowing approval gaps with the US, China is increasingly central to global development strategies.
This executive summary captures key data, regulatory context, and a real-world oncology case study discussed at Tigermed’s ESMO event—offering a grounded perspective on how and why China is becoming an integral part of modern clinical trial design.
Key insights included in this summary:
- How recent regulatory reforms are accelerating IND reviews and approvals
- Why oncology trials are increasingly moving to China
- What enrollment speed and cost efficiencies look like in practice
- How trial quality has evolved—and how it compares globally
- Lessons from a Phase III oncology trial conducted in China
© 2026 Marketing Masters Hub . All rights reserved.